Drugs producing side effect "tinnitus," "hearing impaired," "hyperacusis," and "depression" (Supplementary Table S1) were downloaded from SIDER 2. SIDER contains information on marketed medicines and their recorded adverse drug reactions extracted from public documents and package inserts.
Supplementary adjustment was made on self-reported visual, hearing impairment and ApoE 4 genotype on the subsample of the cohort with blood sampling (n=623).
All Fgfr3 P244R /+ animals in this hybrid background were hearing impaired, regardless of Fgf8 gene dosage (Supplementary Material, Fig. S1).
Supplementary Tables S1, S3, and S4 show drug and target information for tinnitus, hearing impaired, hyperacusis, and depression.
Secondary outcome measures are the results of the whispering voice test (WVT), the Hearing Handicap Inventory for the Elderly Screening Version (HHIE-S) (see online supplementary files 1 and 2) and the answer to three questions concerning self-perceived hearing problems.
To assess the potential relevance of a specific target for a specific adverse event (i.e., tinnitus, hearing loss, hyperacusis, and depression), we applied a χ method previously introduced by Lounkine et al. (Supplementary Tables S5– S5).
Cx30T5M/T5M mice showed mild hearing impairments with significantly increased hearing thresholds of ∼15 dB at all frequencies, whereas Cx30+/T5M mice displayed no significant differences in hearing compared with Cx30+/+ mice (Fig. 2A and Supplementary Material, Fig. S2).
